Neuberger Berman Group LLC Bio N Tech Se Transaction History

Neuberger Berman Group LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$78.36 - $124.66 $1.17 Million - $1.85 Million	-14,872 Closed	0 $0
Q2 2024 Nov 14, 2024	SELL	$80.36 - $102.87 $35,358 - $45,262	-440 Reduced 2.87%	14,872 $1.2 Million
Q2 2024 Aug 13, 2024	SELL	$80.36 - $102.87 $35,358 - $45,262	-440 Reduced 2.87%	14,872 $1.2 Million
Q1 2024 Nov 14, 2024	BUY	$88.96 - $112.35 $45,547 - $57,523	512 Added 3.46%	15,312 $1.41 Million
Q1 2024 May 13, 2024	BUY	$88.96 - $112.35 $1.36 Million - $1.72 Million	15,312 New	15,312 $1.41 Million
Q4 2023 Nov 14, 2024	SELL	$90.91 - $112.75 $6,545 - $8,118	-72 Reduced 0.48%	14,800 $1.56 Million
Q4 2023 Feb 09, 2024	BUY	$90.91 - $112.75 $1.35 Million - $1.67 Million	14,800 New	14,800 $1.56 Million
Q1 2022 May 13, 2022	SELL	$126.25 - $231.85 $145,818 - $267,786	-1,155 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$216.64 - $362.52 $250,219 - $418,710	1,155 New	1,155 $311,000

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.1B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.